These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31094185)

  • 1. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease.
    Akhmedov VA; Gaus OV
    Ter Arkh; 2019 Mar; 91(2):143-148. PubMed ID: 31094185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.
    van Best N; Jansen PL; Rensen SS
    Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota.
    Cui Y; Wang Q; Chang R; Zhou X; Xu C
    J Agric Food Chem; 2019 Mar; 67(10):2754-2762. PubMed ID: 30798598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Bandsma R
    Curr Drug Targets; 2015; 16(12):1324-31. PubMed ID: 25882223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease.
    Puri P; Sanyal AJ
    Clin Liver Dis; 2018 Feb; 22(1):121-132. PubMed ID: 29128052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome.
    Quigley EM; Abu-Shanab A; Murphy EF; Stanton C; Monsour HP
    Semin Liver Dis; 2016 Sep; 36(4):312-316. PubMed ID: 27997970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?
    Betrapally NS; Gillevet PM; Bajaj JS
    Gastroenterology; 2016 Jun; 150(8):1745-1755.e3. PubMed ID: 26948887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
    Lang S; Schnabl B
    Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
    Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
    Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of gut microbial metabolites in nonalcoholic fatty liver disease.
    Zhao ZH; Lai JK; Qiao L; Fan JG
    J Dig Dis; 2019 Apr; 20(4):181-188. PubMed ID: 30706694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
    Bibbò S; Ianiro G; Dore MP; Simonelli C; Newton EE; Cammarota G
    Mediators Inflamm; 2018; 2018():9321643. PubMed ID: 29563854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
    Ji Y; Yin Y; Li Z; Zhang W
    Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.
    Koukias N; Buzzetti E; Tsochatzis EA
    Minerva Endocrinol; 2017 Jun; 42(2):184-194. PubMed ID: 27879962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gut microbiota and nonalcoholic steatohepatitis].
    Kessoku T; Imajo K; Kobayashi T; Honda Y; Ogawa Y; Yoneda M; Saito S; Nakajima A
    Nihon Yakurigaku Zasshi; 2018; 152(4):187-193. PubMed ID: 30298840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.